Abstract
The role of the hypothalamic-pituitary adrenal axis in the host response to infection is crucial. The initial inflammatory response to sepsis activates the endogenous release of cortisol, which in turn modulates the synthesis and release of both pro- and antiinflammatory mediators to restrict inflammation in infected tissues. However, a number of factors, including vascular or ischemic damage, inflammation and apoptosis within the hypothalamic-pituitary adrenal axis, as well as use of drugs that alter cortisol metabolism, may cause adrenal insufficiency. One major problem ICU physicians are faced with is the diagnosis of sepsis-induced adrenal insufficiency at the bedside. A multidisciplinary international task force has recently recommended that sepsis induced adrenal insufficiency is best recognized by basal cortisol of less than 10μg/dl or change in cortisol of less than 9μg/dl after administration of corticotrophin. The diagnostic value of measuring salivary free cortisol in this setting remains to be investigated. While sepsis adrenal insufficiency is undoubtedly associated with a poor prognosis, the indication and practical modalities of corticosteroids therapy remained controversial. Based on the two largest randomised, placebo-controlled trials, many investigators, myself included, contend that septic shock patients with hypotension poorly responsive to fluid replacement and vasopressors should receive a seven day treatment with the combination of hydrocortisone at a dose of 200 mg per day and fludrocortisone at the dose of 50 μg per day.
Keywords: Hypothalamic-pituitary adrenal axis, cytokines, apoptosis, diagnostic criteria, metyrapone, synacthen test, clinical trials, survival
Current Pharmaceutical Design
Title: Adrenal Insufficiency in Sepsis
Volume: 14 Issue: 19
Author(s): Djillali Annane
Affiliation:
Keywords: Hypothalamic-pituitary adrenal axis, cytokines, apoptosis, diagnostic criteria, metyrapone, synacthen test, clinical trials, survival
Abstract: The role of the hypothalamic-pituitary adrenal axis in the host response to infection is crucial. The initial inflammatory response to sepsis activates the endogenous release of cortisol, which in turn modulates the synthesis and release of both pro- and antiinflammatory mediators to restrict inflammation in infected tissues. However, a number of factors, including vascular or ischemic damage, inflammation and apoptosis within the hypothalamic-pituitary adrenal axis, as well as use of drugs that alter cortisol metabolism, may cause adrenal insufficiency. One major problem ICU physicians are faced with is the diagnosis of sepsis-induced adrenal insufficiency at the bedside. A multidisciplinary international task force has recently recommended that sepsis induced adrenal insufficiency is best recognized by basal cortisol of less than 10μg/dl or change in cortisol of less than 9μg/dl after administration of corticotrophin. The diagnostic value of measuring salivary free cortisol in this setting remains to be investigated. While sepsis adrenal insufficiency is undoubtedly associated with a poor prognosis, the indication and practical modalities of corticosteroids therapy remained controversial. Based on the two largest randomised, placebo-controlled trials, many investigators, myself included, contend that septic shock patients with hypotension poorly responsive to fluid replacement and vasopressors should receive a seven day treatment with the combination of hydrocortisone at a dose of 200 mg per day and fludrocortisone at the dose of 50 μg per day.
Export Options
About this article
Cite this article as:
Annane Djillali, Adrenal Insufficiency in Sepsis, Current Pharmaceutical Design 2008; 14 (19) . https://dx.doi.org/10.2174/138161208784980626
DOI https://dx.doi.org/10.2174/138161208784980626 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can We Move Forward After ADVANCE?
Vascular Disease Prevention (Discontinued) Suitable Multicomponent Organic Synthesis using Heteropolycompounds as Catalysts
Mini-Reviews in Organic Chemistry Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Reviews on Recent Clinical Trials Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Diagnosing and Treating Depression in Older and Oldest Old
Current Pharmaceutical Design Synthesis, Spectral Characterization and Anticancer Activity of New 2,3,6- Substituted Quinazolin-4(3H)-one Derivatives
Letters in Organic Chemistry Role of Secondary Alcohol Metabolites in Anthracycline Cardiotoxicity: from Hypotheses to New Drugs
Drug Design Reviews - Online (Discontinued) Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry The Role of NPY and Ghrelin in Anorexia Nervosa
Current Pharmaceutical Design The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology New Approaches to Endothelin Receptor Antagonist-Bosentan
Letters in Organic Chemistry Biological Properties of Citrus Flavonoids Pertaining to Cancer and Inflammation
Current Medicinal Chemistry Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine IgG Dimers in Multidonor-Derived Immunoglobulins: Aspects of Generation and Function
Current Pharmaceutical Design Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Hantaviruses: Molecular Biology, Evolution and Pathogenesis
Current Molecular Medicine